Non-Small Cell Lung Cancer

Latest News

AJMC Q&A with Robert Kratzke | Background image credit: ipopba - stock.adobe.com
Ensuring Coverage of Faster Biomarker Testing in Lung Cancer: Robert Kratzke, MD

July 15th 2025

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving.

Lung cancer | Image credit: appledesign - stock.adobe.com
HALP Score Acts as Prognostic Biomarker for Survival Outcomes in NSCLC

July 14th 2025

IV chemotherapy-Aidman-stock.adobe.com
Patients With Advanced NSCLC Face Critical Treatment Gaps

July 11th 2025

FDA Approved
FDA Approves Sunvozertinib in Non–Small Cell Lung Cancer

July 7th 2025

Alexander I. Spira, MD, PhD | Image: Virginia Cancer Specialists
COCOON Shows How Prophylactic AE Management Boosts QOL When Treating NSCLC With Amivantamab Plus Lazertinib

July 3rd 2025

Advancing ALK+ NSCLC Care: Optimizing Treatment, Sequencing, and Long-Term Outcomes

Get insight to advances in ALK+ NSCLC treatment, including long-term lorlatinib data, new therapy approvals, brain metastasis management, and evolving sequencing strategies with this series.

AJMC Peer Exchange logo
Continuing Medical Education
View All
July 18th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 18th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Melinda C. Aldrich, PhD, MPH, Vanderbilt University
January 5th 2024

Updated Guidelines Expand Lung Cancer Screening Eligibility for At-Risk Patients: Dr Melinda Aldrich

Hayden E. Klein Rose McNulty
Melinda C. Aldrich, PhD, MPH, associate professor in the departments of medicine, thoracic surgery, and biomedical informatics at Vanderbilt University, discussed recently updated lung screening guidelines from the American Cancer Society and the importance of equity across populations as new guidelines are developed.
Michael Gieske, MD
January 5th 2024

Dr Michael Gieske on Addressing Lung Cancer Screening Disparities in Rural America

Pearl Steinzor Rose McNulty
Michael Gieske, MD, director of lung cancer screening at St. Elizabeth Health Care, discusses disparities in lung cancer incidence and mortality that the Rural Appalachian Lung Cancer Screening Initiative aims to address.
DNA | Image credit: BillionPhotos.com - stock.adobe.com
December 20th 2023

Multigene Testing Helpful in Giving Targeted Treatment in NSCLC

Julia Bonavitacola
Patients with non–small cell lung cancer (NSCLC) who tested positive for driver gene alteration had longer overall survival when given targeted therapy.
Lung cancer treatment and prevention concept | Image credit: Dr_Microbe - stock.adobe.com
December 15th 2023

Frontline Serplulimab Plus Chemo Provides Consistent Survival Benefit in Squamous NSCLC

Courtney Flaherty
The addition of serplulimab to carboplatin and nab-paclitaxel significantly prolonged survival vs chemotherapy alone when used in the first-line treatment of patients with previously untreated locally advanced or metastatic squamous non–small cell lung cancer.
Hands holding a model of lungs | Image credit: SewcreamStudio - stock.adobe.com
December 4th 2023

Survival, PROs Favor Cemiplimab Plus Chemotherapy vs Chemotherapy Alone in Advanced NSCLC

Laura Joszt, MA
For patients with advanced non–small cell lung cancer (NSCLC), regardless of PD-L1 status, cemiplimab plus chemotherapy had favorable survival benefits and patient-reported outcomes over chemotherapy alone.
3d rendered medically accurate illustration of lung cancer | SciePro - stock.adobe.com
November 16th 2023

FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1-Positive NSCLC

Pearl Steinzor
Repotrectinib achieved a high objective response rate and durable response in the pivotal TRIDENT-1 trial.
Doctor With X-Ray Image | | Image Credit: GO Imaging - stock.adobe.com
October 14th 2023

Perioperative Pembrolizumab Meets Dual Primary End Point of OS in NSCLC

Kristi Rosa
Pembrolizumab plus chemotherapy prior to surgery, followed by resection and single-agent pembrolizumab in the adjuvant setting, significantly improved overall survival (OS) vs neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in patients with resectable stage II, IIIA, or IIIB (T3-4N2) non–small cell lung cancer, meeting the dual primary end point of the phase 3 KEYNOTE-671 trial.
<12345

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo